Antibody-drug conjugates (ADCs) consist of three core components: a monoclonal antibody, a cytotoxic payload, and a linker that covalently joins the two. The linker is far more than a passive tether — it dictates plasma stability, the timing and location of payload release, and ultimately the therapeutic window and toxicity profile of the drug. An ideal linker must remain stable in systemic circulation (with a half-life roughly ten times longer than the ADC itself) while enabling efficient, selective release of the active drug once the ADC reaches its tumor target.
Core Functions of a Linker
Linkers serve several simultaneous roles beyond simple attachment. They provide a chemical handle for conjugating payload to antibody, they can improve solubility and reduce aggregation of the hydrophobic payload, and they must prevent premature drug release in the bloodstream while ensuring liberation of active drug at the target site. Reactive handles used for conjugation are generally grouped by their site of attachment on the antibody, most commonly lysine or engineered/reduced cysteine residues.
Two Fundamental Linker Classes
ADC linkers fall into two broad mechanistic categories based on how they release the payload: cleavable and non-cleavable. More than 80% of clinically approved ADCs use cleavable linkers, while non-cleavable chemistry has historically been used in fewer approved drugs, most notably ado-trastuzumab emtansine (Kadcyla, T-DM1).
Cleavable Linkers
Cleavable linkers contain a chemical trigger built into the structure that responds to conditions specific to the tumor cell or its microenvironment, allowing controlled, localized drug release. The dominant subtypes are:
-
Protease-sensitive peptide linkers: cleaved by lysosomal proteases (notably cathepsin B) recognizing specific dipeptide sequences such as valine-citrulline (Val-Cit); this is the most widely used cleavable linker strategy in current ADCs, frequently paired with a self-immolative para-aminobenzyl (PAB) spacer that triggers 1,6-elimination to release free drug.
-
Acid-sensitive hydrazone linkers: exploit the pH difference between blood plasma (~7.4) and the acidic tumor microenvironment or lysosome (pH 4.0–6.5) to trigger hydrolysis.
-
Glutathione/disulfide-sensitive linkers: rely on the markedly higher intracellular glutathione concentration in tumor cells compared to plasma to reduce disulfide bonds and release payload.
-
Emerging triggers: β-glucuronidase-cleavable, Fe(II)-cleavable, photo-responsive, and bioorthogonal cleavage chemistries are active areas of newer linker research, though most remain preclinical.
Because the released cleavable-linker payload is typically small, hydrophobic, and membrane-permeable, it can diffuse into neighboring tumor cells regardless of their antigen expression level — a phenomenon called the "bystander effect" that is particularly valuable for treating heterogeneous solid tumors.
Non-Cleavable Linkers
Non-cleavable linkers, such as SMCC (used in Kadcyla) or maleimidocaproyl (MC), contain no built-in chemical or enzymatic trigger. Instead, the payload is only released after the antibody is completely internalized and degraded by lysosomal proteases, meaning the released "metabolite" still carries an attached amino-acid residue plus the linker. This has two important consequences: the ADC exhibits excellent plasma stability and lower systemic toxicity because there is no chemical weak point for premature cleavage, but the resulting metabolite has poor membrane permeability, restricting killing largely to antigen-high cells and eliminating most of the bystander effect.
Structural Anatomy: Beyond Cleavage Chemistry
Modern linker design literature breaks the linker into distinct functional segments: a chemical handle for antibody conjugation (e.g., maleimide for cysteine, NHS ester for lysine), a hydrophilic spacer to improve solubility and reduce aggregation, and a trigger/self-immolative unit that governs payload liberation. Site-specific conjugation technologies — including THIOMAB, SMARTag, microbial transglutaminase-mediated conjugation, glycan remodeling, and AJICAP — have been developed to improve the homogeneity of drug-antibody ratio (DAR) and overall ADC stability compared to older, less controlled conjugation chemistry.
Clinical Impact and Design Trade-offs
Linker choice directly shapes an ADC's therapeutic index. Cleavable linkers generally offer greater potency and bystander killing useful for solid tumors with heterogeneous antigen expression, but at higher risk of off-target toxicity from premature or non-specific cleavage. Non-cleavable linkers trade some potency and bystander activity for a wider safety margin due to superior circulating stability. As of the most recent comprehensive reviews, 17 ADCs have received regulatory approval, and continued innovation in linker triggers, spacer hydrophilicity, and site-specific bioconjugation is the primary lever researchers are using to further widen the therapeutic window of next-generation ADCs.
Reviews:
(1) Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M., & Beck, A. (2023). Antibody–drug conjugates come of age in oncology. In Nature Reviews Drug Discovery (Vol. 22, Issue 8, pp. 641–661). Nature Research. https://doi.org/10.1038/s41573-023-00709-2